Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Zerbaxa (ceftolozane and tazobactam) by Year
Zerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Zerbaxa (ceftolozane and tazobactam): 24.0% in FY2025, up 6.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Zerbaxa | 70 | 74 | 81 | 87 | 312 | 56 | 62 | 64 | 70 | 252 | 24 | 23 | 24 | 24”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zerbaxa (ceftolozane and tazobactam) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.0% | +6.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 18.0% | -12.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 30.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | -101.0% | -111.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 10.0% | – | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
Cite this data
StockData. (2026). Merck Zerbaxa (ceftolozane and tazobactam) (%), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zerbaxa-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.